Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Efficient Correction of Oncogenic KRAS and TP53 Mutations through CRISPR Base Editing
Shady Sayed, Olga Alexandra Sidorova, Alexander Hennig, et al.
Cancer Research (2022) Vol. 82, Iss. 17, pp. 3002-3015
Open Access | Times Cited: 24

Showing 24 citing articles:

Exploring treatment options in cancer: Tumor treatment strategies
Beilei Liu, Hongyu Zhou, Licheng Tan, et al.
Signal Transduction and Targeted Therapy (2024) Vol. 9, Iss. 1
Open Access | Times Cited: 155
Cancer Spheroids and Organoids as Novel Tools for Research and Therapy: State of the Art and Challenges to Guide Precision Medicine
Sanae El Harane, Bochra Zidi, Nadia El Harane, et al.
Cells (2023) Vol. 12, Iss. 7, pp. 1001-1001
Open Access | Times Cited: 65
Comprehensive review of CRISPR-based gene editing: mechanisms, challenges, and applications in cancer therapy
Mohammad Chehelgerdi, Matin Chehelgerdi, Milad Khorramian‐Ghahfarokhi, et al.
Molecular Cancer (2024) Vol. 23, Iss. 1
Open Access | Times Cited: 62
Translating p53-based therapies for cancer into the clinic
Sylvain Peuget, Xiaolei Zhou, Galina Selivanova
Nature reviews. Cancer (2024) Vol. 24, Iss. 3, pp. 192-215
Closed Access | Times Cited: 55
Targeting Mutant p53 for Cancer Treatment: Moving Closer to Clinical Use?
Michael J. Duffy, Minhong Tang, Subhasree Rajaram, et al.
Cancers (2022) Vol. 14, Iss. 18, pp. 4499-4499
Open Access | Times Cited: 33
Harnessing the evolving CRISPR/Cas9 for precision oncology
Tianye Li, Shuiquan Li, Yue Kang, et al.
Journal of Translational Medicine (2024) Vol. 22, Iss. 1
Open Access | Times Cited: 7
CRISPR prime editing for unconstrained correction of oncogenic KRAS variants
Gayoung Jang, Jiyeon Kweon, Yongsub Kim
Communications Biology (2023) Vol. 6, Iss. 1
Open Access | Times Cited: 14
CRISPR applications in cancer diagnosis and treatment
Mingxia Wang, Menghui Chen, Xia Wu, et al.
Cellular & Molecular Biology Letters (2023) Vol. 28, Iss. 1
Open Access | Times Cited: 13
Integrating CRISPR Technology with Key Genetic Markers in Pancreatic Cancer: A New Frontier in Targeted Therapies
Dimitrios Stefanoudakis
SynBio (2025) Vol. 3, Iss. 1, pp. 1-1
Open Access
Could Drug Delivery Systems Be Enhancers for Therapy against KRAS-driven Cancers?
Ramil Khusnutdinov
Reviews and Advances in Chemistry (2025)
Closed Access
Advances in Cancer Gene Therapy: Strategies, Delivery Methods, and Challenges
Anni Lepland, Kadi-Liis Veiman
Methods in pharmacology and toxicology (2025), pp. 105-123
Closed Access
CRISPR/Cas technologies for cancer drug discovery and treatment
Kevin Chang Wang, Thomas M Zheng, Basil P. Hubbard
Trends in Pharmacological Sciences (2025)
Closed Access
Applications of CRISPR-Cas9 for advancing precision medicine in oncology: from target discovery to disease modeling
Mirunalini Ravichandran, Danilo Maddalo
Frontiers in Genetics (2023) Vol. 14
Open Access | Times Cited: 12
Translation into Clinical Practice of the G1-G7 Molecular Subgroup Classification of Glioblastoma: Comprehensive Demographic and Molecular Pathway Profiling
Maria-Magdalena Georgescu
Cancers (2024) Vol. 16, Iss. 2, pp. 361-361
Open Access | Times Cited: 2
Prospects and challenges of CRISPR/Cas9 gene‐editing technology in cancer research
Ning Li, Jiahui Xi, Zi Yin, et al.
Clinical Genetics (2023) Vol. 104, Iss. 6, pp. 613-624
Closed Access | Times Cited: 5
Advances in CRISPR-Cas systems for blood cancer
Bernice A. Monchusi, Phumuzile Dube, Mutsa M. Takundwa, et al.
Progress in molecular biology and translational science (2024), pp. 261-284
Closed Access | Times Cited: 1
Patient-derived tumor organoids: A preclinical platform for personalized cancer therapy
Sébastien Taurin, Reem Alzahrani, Sahar Aloraibi, et al.
Translational Oncology (2024) Vol. 51, pp. 102226-102226
Open Access | Times Cited: 1
CRISPR-Mediated Base Editing: Promises and Challenges for a Viable Oncotherapy Strategy
Lu Huang, Chao Yang, Yan Chen, et al.
Human Gene Therapy (2023) Vol. 34, Iss. 15-16, pp. 669-681
Closed Access | Times Cited: 3
Nucleic Acid-Based Approaches to Tackle KRAS Mutant Cancers
Jimi Kim
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 23, pp. 16933-16933
Open Access | Times Cited: 3
CasRx-Based Kras G12D Silencing for In Vivo Tumor Inhibition in Spontaneous Lung Adenocarcinoma
Xiaojing Wang, Fei Liu, Lingling Xu, et al.
Research Square (Research Square) (2024)
Open Access
An Overview of Emerging Trends in Gene Therapy for Cancer Treatment
Muhammad M. Amin
American Journal of Clinical and Experimental Medicine (2024) Vol. 12, Iss. 2, pp. 13-19
Open Access
Patientenabgeleitete 3-D-Tumormodelle
Ivona Mateska, Daniel E. Stange, Claudia R. Ball
Deleted Journal (2024)
Closed Access
CRISPR-mediated reversion of oncogenic KRAS mutation results in increased proliferation and reveals independent roles of Ras and mTORC2 in the migration of A549 lung cancer cells
Alyssa N. Werner, Avani I. Kumar, Pascale G. Charest
Molecular Biology of the Cell (2023) Vol. 34, Iss. 13
Open Access | Times Cited: 1
CRISPR prime editing for unconstrained correction of oncogenicKRASvariants
Gayoung Jang, Jiyeon Kweon, Yongsub Kim
bioRxiv (Cold Spring Harbor Laboratory) (2022)
Open Access | Times Cited: 1
Page 1

Scroll to top